The FDA designated 166 products under its breakthrough devices program in its most recent financial year, reversing the ...

A “bioadaptive” stent might circumvent the slow accumulation of target lesion failure that has been a consistent weakness of ...

Abbott, Medtronic, Boston Scientific Corporation ... the market is segmented based on product type (drug-eluting stent (DES), ...

To improve the management of coronary artery disease and lay the groundwork for future advancements in stent technology, ...

The global coronary artery bypass graft market, valued at USD 17,612.1 million in 2023, is forecast to experience significant growth, reaching an estimated USD 22,765.9 million by 2033. While the ...

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final two rounds ...

The 2024 edition of Transcatheter Cardiovascular Therapeutics (TCT) once again highlighted significant innovations in ...

The global market for Drug Device Combination Products was estimated at US$114.8 Billion in 2023 and is projected to reach US$158.7 Billion by 2030, growing at a CAGR of 4.7% from 2023 to 2030. This ...

Hello Health Rounds Readers! Today we have three studies presented at medical meetings, including one testing a device that ...

Results from the large-scale randomized ECLIPSE trial found that a lesion preparation strategy of routine orbital atherectomy had similar outcomes compared with conventional balloon angioplasty prior ...

Data highlighted the success of DynamX compared to Medtronic’s Resolute Onyx zotarolimus drug-eluting stent (DES). The study ...

After years of iterative refinements, drug-eluting stents (DES) have become the standard for percutaneous coronary intervention (PCI). 1-year rates of revascularisation and thrombosis with ...